Pretax income is the income that a company earns before paying income taxes. Biocept's pretax income for the
three
months ended in Jun. 2023 was $-3.63 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was $-30.73 Mil.
Biocept's pretax margin was -616.47%.
During the past 12 years, Biocept's highest Pretax Margin was -4.41%. The lowest was -11928.57%. And the median was -512.73%.
Biocept Pre-Tax Income Historical Data
The historical data trend for Biocept's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biocept's Pre-Tax Income
For the Diagnostics & Research subindustry, Biocept's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Biocept's Pre-Tax Income falls into.
Biocept Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Biocept's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept (OTCPK:BIOCQ) Pre-Tax Income Explanation
Biocept's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as
During the past 12 years, Biocept's highest Pretax Margin was -4.41%. The lowest was -11928.57%. And the median was -512.73%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Biocept's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOCQ has been successfully added to your 